![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC2A5 |
Gene summary for SLC2A5 |
![]() |
Gene information | Species | Human | Gene symbol | SLC2A5 | Gene ID | 6518 |
Gene name | solute carrier family 2 member 5 | |
Gene Alias | GLUT-5 | |
Cytomap | 1p36.23 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A140VJK5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6518 | SLC2A5 | Pat01-B | Human | Stomach | GC | 7.33e-13 | 3.63e-01 | 0.5754 |
6518 | SLC2A5 | Pat03-B | Human | Stomach | GC | 8.21e-08 | 2.58e-01 | 0.3693 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007586 | Stomach | GC | digestion | 38/1159 | 137/18723 | 1.80e-15 | 1.22e-12 | 38 |
GO:00226006 | Stomach | GC | digestive system process | 30/1159 | 104/18723 | 5.40e-13 | 2.10e-10 | 30 |
GO:00508925 | Stomach | GC | intestinal absorption | 18/1159 | 41/18723 | 8.10e-12 | 2.20e-09 | 18 |
GO:00097436 | Stomach | GC | response to carbohydrate | 40/1159 | 253/18723 | 4.13e-08 | 2.85e-06 | 40 |
GO:00342846 | Stomach | GC | response to monosaccharide | 37/1159 | 225/18723 | 4.67e-08 | 3.17e-06 | 37 |
GO:00097466 | Stomach | GC | response to hexose | 36/1159 | 219/18723 | 7.14e-08 | 4.62e-06 | 36 |
GO:00713315 | Stomach | GC | cellular response to hexose stimulus | 25/1159 | 153/18723 | 7.68e-06 | 2.77e-04 | 25 |
GO:00713265 | Stomach | GC | cellular response to monosaccharide stimulus | 25/1159 | 154/18723 | 8.64e-06 | 2.97e-04 | 25 |
GO:00713225 | Stomach | GC | cellular response to carbohydrate stimulus | 25/1159 | 163/18723 | 2.36e-05 | 6.90e-04 | 25 |
GO:0003044 | Stomach | GC | regulation of systemic arterial blood pressure mediated by a chemical signal | 11/1159 | 47/18723 | 1.08e-04 | 2.09e-03 | 11 |
GO:0009750 | Stomach | GC | response to fructose | 5/1159 | 10/18723 | 1.75e-04 | 3.05e-03 | 5 |
GO:0003073 | Stomach | GC | regulation of systemic arterial blood pressure | 14/1159 | 96/18723 | 2.29e-03 | 2.21e-02 | 14 |
GO:0008217 | Stomach | GC | regulation of blood pressure | 22/1159 | 186/18723 | 2.66e-03 | 2.46e-02 | 22 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC2A5 | SNV | Missense_Mutation | novel | c.265G>T | p.Val89Phe | p.V89F | P22732 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SLC2A5 | SNV | Missense_Mutation | novel | c.170G>A | p.Arg57Lys | p.R57K | P22732 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-NK-A5D1-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | gemcitabine | PD |
SLC2A5 | SNV | Missense_Mutation | novel | c.439C>G | p.Pro147Ala | p.P147A | P22732 | protein_coding | deleterious(0.01) | possibly_damaging(0.887) | TCGA-CN-4735-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | vectibix | SD |
SLC2A5 | deletion | Frame_Shift_Del | novel | c.28delN | p.Glu10LysfsTer4 | p.E10Kfs*4 | P22732 | protein_coding | TCGA-CN-4728-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | vectibix | SD | ||
SLC2A5 | SNV | Missense_Mutation | novel | c.37C>A | p.Leu13Met | p.L13M | P22732 | protein_coding | tolerated(0.07) | benign(0.115) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
SLC2A5 | SNV | Missense_Mutation | rs138176474 | c.331N>A | p.Val111Met | p.V111M | P22732 | protein_coding | deleterious(0.04) | possibly_damaging(0.72) | TCGA-ZG-A9L6-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | PD |
SLC2A5 | SNV | Missense_Mutation | c.779C>T | p.Ala260Val | p.A260V | P22732 | protein_coding | tolerated(0.31) | benign(0.015) | TCGA-BR-8382-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SLC2A5 | SNV | Missense_Mutation | c.59C>T | p.Ala20Val | p.A20V | P22732 | protein_coding | tolerated(0.44) | benign(0.11) | TCGA-D7-A4YV-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC2A5 | SNV | Missense_Mutation | c.227C>T | p.Ser76Phe | p.S76F | P22732 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-HF-7133-01 | Stomach | stomach adenocarcinoma | Female | Unknown | III/IV | Chemotherapy | epirubicin | SD | |
SLC2A5 | SNV | Missense_Mutation | c.1022G>A | p.Arg341Gln | p.R341Q | P22732 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-HU-A4G9-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6518 | SLC2A5 | TRANSPORTER, DRUGGABLE GENOME | STREPTOZOTOCIN | STREPTOZOCIN | 9756334 | |
6518 | SLC2A5 | TRANSPORTER, DRUGGABLE GENOME | GLUFOSFAMIDE | GLUFOSFAMIDE |
Page: 1 |